PATENT CLAIM ANALYSIS

Application Number: 16065470
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-03
Patent Classification: ["514", "314000"]

Abstract:
The present invention relates to methods of treating patients with WHIM syndrome or related disorders, such as myelokathexis, in which X4P-001 is administered in order to reduce the activity of CXCR4. The methods demonstrate surprising effectiveness, with comparatively little toxicity.

Claim (Index 2):
The method of  claim 1 , wherein the X4P-001 or a pharmaceutically acceptable salt hereof is administered in a dose of from about 25 mg/day to about 150 mg/day.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 94.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14705809', '13651385', '14947173', '12374311', '15021323']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7133111792366577
- 35 USC 102 Novelty (BERT): 0.5232957647451868
- Combined Prediction Score: 0.6943096377875105
- Mean Citation Score: 171.55361599999995
- Max Citation Score: 182.39935
- Similarity Product: 95.5738327673137

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test